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Abstract 10 
Nowadays, many pharmaceuticals are detected in surface waters around the world. Because of the 11 
extent of the issue, monitoring alone cannot provide a complete overview of the situation. To guide 12 
smart monitoring efforts and optimal mitigation measures, spatially explicit models can be used. We 13 
show that geographical variability leads to substantial differences in environmental exposure to 14 
pharmaceuticals, even at the level of single prescriptions. Application of a multimedia fate modelling 15 
approach indicated that in Europe, Spanish infants eating locally produced crops have the highest 16 
relative health risks due to exposure to antibiotics. For smaller scale assessments, for example 17 
identification of local hotspots or running specific local scenario analyses, we propose the use of 18 
geographic-based single-media models. 19 
Introduction 20 
Since ancient times humans have used natural resources for the treatment of disease. Indeed, 21 
archaeological evidence suggests that natural antibiotics and laxatives were already used in 22 
prehistorical times (Capasso, 1998), and the first structural documentations of Egyptian and Chinese 23 
medicine date back more than 3000 years (Raviña, 2011). However, it took until halfway through the 24 
nineteenth century for modern day medicine to arise. Facilitated by the emergence of the sciences of 25 
pharmacology and synthetic organic chemistry, the already present apothecaries began their 26 
transition into pharmaceutical companies (Winquist et al., 2014). Since then, they have grown into 27 
the global enterprises they are today, contributing significantly to the worldwide increase in life 28 
expectancy (Roser, 2017). Along the way, the originally empirical chemistry-driven search for new 29 
pharmaceuticals shifted towards a target-based biology-driven approach in which new 30 
pharmaceuticals are designed rather than discovered. Consequently, newly developed 31 
pharmaceuticals have become increasingly effective through designing for potency, bioavailability and 32 
 2 
degradation resistance, and many are now globally detected in the aquatic environment (aus der Beek 33 
et al., 2016).  34 
Approximately 1500 active pharmaceutical ingredients are currently in use (Guo et al., 2016; Kinch et 35 
al., 2014), many of which we are yet unable to detect at environmentally relevant concentrations. 36 
Consequently, monitoring will provide at most a patchy and incomplete view of the global situation. 37 
There is therefore a need for exposure modelling approaches that can help us prioritize our monitoring 38 
efforts and that can be used to take targeted measures. These should preferably be spatially explicit, 39 
acknowledging that geographical variability can lead to substantial differences in concentrations 40 
across and within regions (Oldenkamp et al., 2016). 41 
Methods 42 
Predicted environmental concentrations (PECs) of chemicals can be derived using multimedia fate 43 
models, such as the EUSES model (Vermeire et al., 2005) or our prioritisation tool for APIs (Oldenkamp 44 
et al., 2013). Such models are based on mass-balance equations for interconnected compartments 45 
that represent the relevant environmental media (e.g., fresh and salt waters, air, urban and 46 
agricultural soils, et cetera), and are especially useful for larger scale (regional, continental) 47 
assessments where multiple media might be relevant. A typical application is the geographical 48 
prioritisation of pharmaceuticals based on their potential human health impact, since human 49 
exposure might occur via multiple pathways (e.g., drinking water, crops, fish). Invariably, 50 
environmental fate models estimate PECs of pharmaceuticals by integrating information on 51 
pharmaceutical usage, human metabolism, removal during wastewater treatment, dilution and 52 
dissipation in the receiving environmental compartments, and transport between them. For the 53 
estimation of human exposure, environmental concentrations are combined with additional 54 
information on the chemical’s potential for uptake by crops and fish, and information on consumption 55 
and behavioural patterns of the exposed (sub-)population.  56 
Results 57 
Spatially explicit modelling of the environmental medicine chain in Europe identified Spanish infants 58 
eating locally produced crops as having the highest relative health risks due to environmental 59 
exposure to antibiotics (Figure 1; Oldenkamp et al., 2013). This can be traced back to surplus sewage 60 
sludge extensively spread on Spanish agricultural soils. Because of the (semi-)arid climate, antibiotic 61 
residues contained in this sludge undergo little runoff to surface waters or leaching into lower soil 62 
layers. This makes them available for uptake by crops and subsequent consumption. In fact, the spatial 63 
variation in environmental conditions throughout Europe even affects relative impacts at the level of 64 
single prescriptions: the environmentally conscious choice between two comparable alternative 65 
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pharmaceuticals (e.g. the fluoroquinolones ciprofloxacin and levofloxacin), differs from location to 66 
location (Figure 2; Oldenkamp et al., 2014).  67 
 68 
Figure 1. Summed health risk quotients (predicted exposure ÷ HD50) for infants in Europe, due to 69 
exposure to antibiotics after consumption of locally produced food; inset: visualization of most 70 
important exposure route (adapted from Oldenkamp et al., 2013). 71 
 72 
Figure 2. Relative impact of one prescription of ciprofloxacin (blue bars) compared to one prescription 73 
of levofloxacin (yellow bars) on the aquatic environment and human health in East Sweden or North 74 
Italy (adapted from Oldenkamp et al., 2014). 75 
Discussion 76 
 4 
Relative risks of antibiotics in the environment, based on their potential impacts on human health and 77 
the aquatic environment, show substantial geographical variation throughout Europe. Because of 78 
their inclusion of multiple environmental media, and the relatively large spatial scale at which they 79 
predict, their applicability could be extended in a relative straightforward way to include diffuse 80 
sources of veterinary pharmaceuticals. Multimedia fate models are, however, less suitable for 81 
answering locally specific questions (e.g., hotspot identification, scenario analyses for optimal 82 
mitigation measures), because they assume a homogenous distribution of chemicals over their 83 
compartments and do not account for any spatial variation at that scale (Pistocchi et al., 2010). 84 
Considering that pharmaceuticals largely remain in the environmental compartment where they are 85 
emitted (i.e., surface water or agricultural soils; Żukowska et al., 2006), single-media models form a 86 
suitable alternative for local assessments where a single environmental medium is relevant. Examples 87 
of geographic-based single-media models for down-the-drain chemicals are GREAT-ER (Feijtel et al., 88 
1997), PhATE (Anderson et al., 2004), GWAVA (Dumont et al., 2012), LF2000-WQX (Williams et al., 89 
2009) and iSTREEM (Kapo et al., 2016). 90 
Conclusion 91 
Multimedia fate models are suitable tools for the geographical prioritisation of pharmaceuticals in the 92 
environment. For the specific case of direct effects of antibiotics, we have shown that a spatially 93 
explicit approach to prioritisation is essential.  94 
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